Edwards Skids On Weak Expectations For Its Bread-And-Butter Moneymaker
Edwards Lifesciences stock fell Friday after the company said its TAVR segment will face numerous challenges in the fourth quarter. Continue reading View comments
- Supported exchanges /
- SA /
- E1WL34.SA
Edwards Lifesciences Corporation (E1WL34 SA) stock market data APIs
R$95.39
0(0%)
as of November 12, 2024
Price chart is built with Anychart
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation Financial Data Overview
| 95.39 | |
| 95.39 | |
| - | |
| 95.39 | |
| 95.39 | |
| 80.01-129.61 | |
| 227 875 M | |
| 26.2473 | |
| 2 359 M | |
| 6 315 M | |
| 1.12 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'E1WL34',
Type:
'Common Stock',
Name:
'Edwards Lifesciences Corporation',
Exchange:
'SA',
CurrencyCode:
'BRL',
CurrencyName:
'Brazilian real',
CurrencySymbol:
'R$',
CountryName:
'Brazil',
CountryISO:
'BR',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Medical Devices',
}
Edwards Lifesciences Corporation Fundamental Data is available in our Financial Data APIs
- Net Revenue 6 315 M
- EBITDA 2 052 M
- Earnings Per Share 3.68
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Edwards Lifesciences Corporation Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Edwards Lifesciences Corporation End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Edwards Lifesciences Corporation latest news via APIs
Edwards Lifesciences (EW) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.67 per share, reflecting an increase of 13.6% compared to the same period last y...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
